Lepodisiran

Lepodisiran (LY3819469) is a small interfering RNA that was developed to reduce lipoprotein(a) in people at risk of cardiovascular disease. It was developed by Eli Lilly and Company.[1][2]

Lepodisiran
Clinical data
Other namesLY3819469; LY-3819469
Legal status
Legal status
  • Investigational
Identifiers
CAS Number
UNII

References
  1. Nissen, Steven E.; Linnebjerg, Helle; Shen, Xi; Wolski, Kathy; Ma, Xiaosu; Lim, Shufen; Michael, Laura F.; Ruotolo, Giacomo; Gribble, Grace; Navar, Ann Marie; Nicholls, Stephen J. (12 November 2023). "Lepodisiran, an Extended-Duration Short Interfering RNA Targeting Lipoprotein(a): A Randomized Dose-Ascending Clinical Trial". JAMA. 330 (21): 2075–2083. doi:10.1001/jama.2023.21835. ISSN 0098-7484. PMC 10641766. PMID 37952254.
  2. Boyanovsky, Boris B. (July 2023). "Lipoprotein(a) Lowering Medications: Another Step Forward in Atherosclerosis Management". Journal of Cardiovascular Pharmacology. 82 (1): 32–36. doi:10.1097/FJC.0000000000001438. PMID 37192439.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.